As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period…
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.
Gilead Sciences Inc. announced a new R&D collaboration Dec. 20 centered on transforming growth factor beta (TGFß) inhibitors for fibrotic disease under an agreement with Scholar Rock Holding Corp.. One day earlier, the Foster City, Calif.-based firm signed a deal to collaborate in immuno-oncology with Agenus Inc
The sector is continuing to show resilience despite financial and market challenges.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.
